The Rx Recap: February 23 – March 1

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

New Machine-Learning Approach Could Speed Precision Drug Development

An article by Medical Device and Technology highlights a breakthrough in precision therapy development using a deep learning method called Molecular Surface Interaction Fingerprinting (MaSIF). Developed by an Austrian research team and published in Nature, MaSIF utilizes geometric deep learning to design custom protein binders that activate only in the presence of specific drug-bound target proteins. By analyzing protein surface interactions, this approach enables more precise and safer immunotherapies. Proof-of-concept tests showed high-affinity binding to various drug-protein complexes, demonstrating its potential for applications in oncology and other therapeutic fields.

Recent Clinical Study for Belight3 Shows Decrease in Hyperpigmentation for All Skin Types

An article by Nutritional Outlook discusses a recent clinical study on Belight3, a nutritional supplement designed to reduce hyperpigmentation and promote even-toned skin. Belight3 contains a patented blend of licorice extract, coated vitamin C, grape seed extract, and grape pomace extract, which reportedly inhibits tyrosinase activity by 85%. In a 12-week study involving 66 participants with lighter skin tones, those taking Belight3 showed a 22% improvement in dark spots and overall complexion. Consumer satisfaction reached 82%, with visible results appearing after just 11 days. Previous research on Asian skin also demonstrated Belight3’s efficacy in reducing dark spots. Activ’Inside, the company behind Belight3, will host webinars to discuss its benefits in Europe and the Americas.

Agree to Disagree: A Collaborative Perspective From a Treatment Team and Disagreeing Patient

This article from Psychiatric Times explores the case of "Dr. Jones," a psychiatrist hospitalized for altered mental status, whose diagnosis of bipolar I disorder was met with resistance due to professional identity, stigma, and concerns about career implications. Despite evidence from collateral sources supporting a pattern of manic episodes, Dr. Jones attributed her symptoms to neurological and endocrine conditions. The article presents perspectives from both the treatment team and the patient, highlighting the ethical challenges of diagnosis among medical professionals. It discusses the impact of stigma, mandatory reporting concerns, and the need for improved mental health support for providers.

AI Haptic Feedback Technology Reduced Nocturnal Scratching in Atopic Dermatitis

An article by Drug Topics highlights a study published in JAMA Dermatology on the use of haptic feedback technology to reduce nocturnal scratching in patients with mild atopic dermatitis (AD). The AI-powered wearable device effectively decreased both scratch time and frequency, addressing a key challenge in AD management. Researchers noted that while pharmacologic treatments like topical steroids and dupilumab injections are commonly used, there is a need for nonsystemic interventions, particularly for patients experiencing severe itching despite mild skin involvement.

The study involved 10 participants with AD, and the device demonstrated 99% accuracy, 95% sensitivity, and 99% specificity in detecting scratching behaviors. The haptic feedback system led to a 28% reduction in total scratch events and a 40% decrease in total scratch duration, significantly improving sleep quality and overall disease management. Most participants found the device easy to use, suggesting its potential as a standalone or supportive therapy for those seeking nonpharmacologic options. Future studies are expected to further validate the efficacy of haptic feedback in treating AD.

Successfully Implementing AI Into Your Practice: A Strategic and Tactical Approach

An article by Physicians Practice explores the strategic integration of Artificial Intelligence (AI) into healthcare organizations. While AI adoption has progressed, a 2024 AMA study found that only 38% of doctors use AI, and enthusiasm remains mixed, with just 27% of healthcare staff viewing it positively, according to a HIMSS report.

To bridge this gap, the article outlines a dual-pronged approach—strategic planning and tactical execution. A strong AI strategy involves defining objectives, developing a deployment roadmap, and assessing workflows. Practical steps for implementation include appointing an AI champion, starting with a single use case, educating patients with signage, and equipping staff with AI talking points to ease concerns.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.